Novel mechanisms underlying major childhood neuromuscular disease identified
Motor circuits malfunction in lethal childhood disease (image of fly spinal cord equivalent). Credit: Brian McCabe, PhD/Columbia University Medical Center
A study by scientists from the Motor Neuron Center at Columbia University Medical Center (CUMC) suggests that spinal muscular atrophy (SMA), a genetic neuromuscular disease in infants and children, results primarily from motor circuit dysfunction, not motor neuron or muscle cell dysfunction, as is commonly thought. In a second study, the researchers identified the molecular pathway in SMA that leads to problems with motor function. Findings from the studies, conducted in fruit fly, zebrafish and mouse models of SMA, could lead to therapies for this debilitating and often fatal neuromuscular disease. Both studies were published today in the online edition of the journal Cell.
"Scientists call SMA a motor neuron disease, and there is post-mortem evidence that it does cause motor neurons to die," said Brian McCabe, PhD, assistant professor of pathology and cell biology and of neuroscience in the Motor Neuron Center, who led the first study. "However, it was not clear whether the death of motor neurons is a cause of the disease or an effect. Our findings in the fruit fly SMA model show that the disease originates in other motor circuit neurons, which then causes motor neurons to malfunction."
In motor circuits, which coordinate muscle movement, specialized sensory neurons called proprioceptive neurons pick up and relay information to the spinal cord and brain about the body's position in space. The central nervous system then processes and relays the signals, including via interneurons, to motor neurons, which in turn stimulate muscle movement.
"To our knowledge, this is the first clear demonstration in a model organism that defects in the function of a neuronal circuit are the cause of a neurological disease," added Dr. McCabe.
SMA is a hereditary neuromuscular disease characterized by muscle atrophy and weakness. The disease is caused by defects in a gene called SMN1 (survival motor neuron 1), which encodes the SMN protein. There are several forms of SMA, distinguished by time of onset and clinical severity. The most severe form, Type 1, appears before six months of age and generally results in death by age two. In milder forms, symptoms may not appear until much later in childhood or even in early adulthood. There is no treatment for SMA, which is estimated to affect as many as 10,000 to 25,000 children and adults in the United States and is the leading genetic cause of death in infants.
To study the cause of SMA, the researchers worked with fruit flies that had been genetically altered so that every cell had a defective copy of the SMN1 gene. The flies' cells contained low levels of SMN protein, resulting in reduced muscle size and motor function, much as in humans with SMA. When fully functional copies of SMN1 were introduced into the flies' motor neurons or muscle cells, the cell types previously thought to be affected, the flies unexpectedly showed no improvement. Only when SMN1 was returned to other motor circuit neurons—in particular, proprioceptive neurons and interneurons—were muscle size and motor function restored.
In further experiments, the researchers demonstrated that in fruit flies with defective SMN1, proprioceptive neurons and interneurons do not produce enough neurotransmitters. When the flies' potassium channels were genetically blocked—thereby increasing neurotransmitter output—muscle size and motor function improved. The same effect was seen when the flies were given drugs that block potassium channels, suggesting that this class of drugs might help patients with SMA.
Supported by these findings, in July, the SMA Clinical Research Center at CUMC launched a clinical trial of a potassium channel blocker called dalfampridine (Ampyra) for the treatment of patients with SMA. The study will assess whether the drug improves walking ability and endurance in adults with SMA Type 3, compared with placebo. Claudia A. Chiriboga, MD, MPH, associate professor of Clinical Neurology at CUMC, is the lead clinical investigator. Ampyra was approved by the FDA for the treatment of patients with multiple sclerosis in 2010.
"This drug is unlikely to be a cure for SMA, but we hope it will benefit patient symptoms," said Dr. McCabe. "Other compounds at various stages of development hold promise to fix the underlying molecular problem."
The second study, led jointly by Livio Pellizzoni, PhD, assistant professor of Pathology and Cell Biology in the Motor Neuron Center, and Dr. McCabe, sought to determine how the loss of SMN protein—which is expressed in all cells—leads to the selective disruption of motor circuits. Working with models of SMA in mammalian cells, fruit flies, zebrafish, and mice, the researchers demonstrated that SMN1 deficiency disrupts a fundamental cellular process known as RNA splicing with detrimental effects on the expression of a subset of genes that contain a rare type of intron. (In the process of RNA splicing, parts of RNA called introns are removed so a gene can be translated into protein.) By studying the function of this group of genes affected by the loss of SMN1, the researchers discovered a novel gene—which they named stasimon—that is critically required for motor circuit activity in vivo. They further showed that restoring expression of stasimon was alone sufficient to correct key aspects of motor dysfunction in both invertebrate and vertebrate models of SMA.
"What is intriguing about SMA is that mutations in the disease gene SMN1 reduce its expression in all cells, yet patients get this specific disease of the motor system. The reason for this has been a longstanding enigma in the SMA field," said Dr. Pellizzoni. "Our findings provide the first explanation at the molecular level as to how this can happen. We show a direct link from the loss of the SMN1 gene to defective splicing of a critical neuronal gene to motor circuit dysfunction, establishing SMA as a disease of RNA splicing. By linking SMN-dependent splicing events to motor circuit function, our work has implications for understanding the pathogenic mechanisms not only of SMA, but also of other neurological disorders," said Dr. Pellizzoni.
"The potential added value of our study is that we've identified a novel gene that is targeted by the disease protein. When disrupted, this gene—stasimon—appears to contribute to the development of SMA in model organisms. The implication is that this gene and the pathway in which it functions might be new candidate therapeutic targets," Dr. Pellizzoni added.
More information: The first paper is titled, "SMN is required for sensory-motor circuit function in Drosophila." The second paper is titled, "A SMN-Dependent U12 Splicing Event Essential for Motor Circuit Function."
Journal reference: Cell
Provided by Columbia University Medical Center
- Communication breakdown: Early defects in sensory synapses in motor neuron disease Feb 09, 2011 | not rated yet | 0
- Toward an effective treatment for a major hereditary disease Oct 13, 2008 | not rated yet | 0
- Researchers discover target that could ease spinal muscular atrophy symptoms Jan 07, 2009 | not rated yet | 0
- Low oxygen levels may decrease life-saving protein in spinal muscular atrophy Aug 21, 2012 | not rated yet | 0
- Researchers gain new insights on spinal muscular atrophy May 29, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
13 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
By discovering the new mechanism by which estrogen suppresses lipid synthesis in the liver, UC Irvine endocrinologists have revealed a potential new approach toward treating certain liver diseases.
Medical research 1 hour ago | not rated yet | 0 |
Aortic arch pulse wave velocity, a measure of arterial stiffness, is a strong independent predictor of disease of the vessels that supply blood to the brain, according to a new study published in the June issue the journal ...
Medical research 1 hour ago | not rated yet | 0
Since the discovery of Prontosil in 1932, sulfonamide antibiotics have been used to combat a wide spectrum of bacterial infections, from acne to chlamydia and pneumonia. However, their side effects can include serious neurological ...
Medical research 3 hours ago | not rated yet | 0 |
Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as the sensation of ...
Medical research 3 hours ago | 5 / 5 (1) | 0 |
Spanish researchers have discovered that the daily clearance of neutrophils from the body stimulates the release of hematopoietic stem cells from the bone marrow into the bloodstream, according to a report published today ...
Medical research 5 hours ago | 5 / 5 (1) | 0
Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...
1 hour ago | not rated yet | 0 |
Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...
6 minutes ago | not rated yet | 0
Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...
10 minutes ago | not rated yet | 0
(HealthDay)—A shortage of a critical tuberculosis drug has hampered the efforts of health departments across the United States to contain the spread of the highly infectious lung disease, federal officials ...
10 minutes ago | not rated yet | 0
Finnish researchers unveiled new data Thursday to link the Pandemrix flu vaccine to a higher risk of the sleeping disorder narcolepsy in adults.
1 hour ago | not rated yet | 0
Maintaining a heart healthy lifestyle may also help protect chronic kidney disease patients from developing kidney failure and dying prematurely, according to a study appearing in an upcoming issue of the Journal of the Am ...
30 minutes ago | not rated yet | 0